Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Shrinking team NBB
FTE fell two years in a row, from 2.9 to 1.6.
Financials
Financial year 2025
LA ROCHE PHARMA from La Roche-en-Ardenne, company number BE0811636216, closed financial year 2025 with a result of € 100,057 after tax. For that financial year LA ROCHE PHARMA recorded a gross margin of € 536,756 and equity of € 851,597. Compared with financial year 2024, the result moved from € 72,056 to € 100,057. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.
€ 851,597
▼ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 100,057
▲ 39% vs 2024
Profit after tax over the fiscal year.
€ 481,886
▼ 18% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 126,432 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
1.6
▼ 0.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 144,109
▲ 16% vs 2024
€ 90,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 42,276
▲ € 36,255 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 507,203
▼ 1% vs 2024
€ 79,870 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 149,727
▲ 16% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 68,061
▲ 22% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 495,572 | € 515,272 | € 507,524 | € 536,756 | ▲ 6% |
| Profit after taxes | € 53,873 | € 51,925 | € 72,056 | € 100,057 | ▲ 39% |
| Equity | € 755,691 | € 807,616 | € 877,972 | € 851,597 | ▼ 3% |
| Total debts | € 1,565,936 | € 1,377,263 | € 1,468,930 | € 1,117,897 | ▼ 24% |
| Cash | € 456,763 | € 501,842 | € 586,112 | € 481,886 | ▼ 18% |
| Land & buildings | € 437,406 | € 407,877 | € 637,254 | € 432,136 | ▼ 32% |
| Retained profit | € 655,691 | € 707,616 | € 777,972 | € 751,597 | ▼ 3% |
| Dividend | € 1,600 | € 0 | € 1,700 | € 126,432 | ▲ € 124,732 |
| Bank debt | € 842,524 | € 682,642 | € 514,019 | € 507,203 | ▼ 1% |
| Balance sheet total | € 2,321,627 | € 2,184,878 | € 2,346,902 | € 1,969,493 | ▼ 16% |
| Employees (FTE) | - | 2.9 | 2.3 | 1.6 | ▼ 0.7 |
By gross margin, LA ROCHE PHARMA ranks 12th of 71 companies with main activity “Detailhandel in farmaceutische producten” in the province of Luxembourg that publish figures (fiscal year 2025).
Key figures of LA ROCHE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about LA ROCHE PHARMA the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to LA ROCHE PHARMA?
What happened at LA ROCHE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 100,057 (▲ 39% vs 2024). filed late Source: NBB ↗
- MARIE-THERESE GIGOT STEPHANIE became a director. NBB
- POL DEFOY JULIEN became a director. NBB
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in La Roche-en-Ardenne. KBO
In short
From € 53,873 profit in 2022 to € 100,057 profit in 2025.
Paid € 279,408 in corporate taxes since 2022.
Best year ever: 2025, with € 100,057 profit.
On average € 335,500 of value added per employee in 2025.
Management
Behind LA ROCHE PHARMA are MARIE-THERESE GIGOT STEPHANIE and POL DEFOY JULIEN.
Directors
According to the 2025 annual accounts
MARIE-THERESE GIGOT STEPHANIE
Director
since 2021
POL DEFOY JULIEN
Director
since 2021
Establishments
Establishment units
Physical locations of this company
Place du Marché 6
6980 La Roche-en-Ardenne
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in the province of Luxembourg
Same main activity (Detailhandel in farmaceutische producten), 74 active companies in the province of Luxembourg, largest first.
€ 1.2 million gross margin · 2025 · Bastogne
€ 926,291 gross margin · 2025 · Bastogne
€ 844,501 gross margin · 2025 · Marche-en-Famenne
€ 832,338 gross margin · 2025 · Durbuy
€ 775,598 gross margin · 2025 · Wellin
€ 760,921 gross margin · 2025 · Arlon
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- DEFOY Julien Pol Francis Ghislain(oprichter) 50%
- GIGOT Stéphanie Marie-Thérèse Nicole Julienne(oprichter) 50%
Details
- Company number
- 0811.636.216
- VAT number
- BE 0811.636.216
- Registered office
- Place du Marché 6, 6980 La Roche-en-Ardenne
- Names & denominations
- LA ROCHE PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 11 May 2009
- Peppol
- Active · Active since 11 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Activiteiten van holdings
Holdings